University of Reims   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Grand Est France (1971)

Organization Overview

First Clinical Trial
2005
NCT02837835
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Central Hospital, Reims, France | Centre Jean Godinot-Reims | CHRU Reims | CHU de Reims | CHU Reims | CHU REIMS | Institut Jean-Godinot | Institut Jean Godinot - Reims | Professor of Neurology, Neurology Department & University of Reims | Reims (FR), Regional University College Hospital | Université de Reims Champagne-Ardenne | University Hospital, Reims

Active Ingredients

Drugs in Phase 4 Trials (6)

atracurium (tracurium) (1 trial)

cisatracurium (nimbex) (1 trial)

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil) (1 trial)

propofol (diprivan) (2 trials)

sodium chloride (1 trial)

sufentanil (1 trial)

Drugs in Phase 3 Trials (13)

bortezomib (velcade) (1 trial)

cabazitaxel (jevtana kit) (1 trial)

ceftazidime (fortaz) (1 trial)

epinephrine (levophed) (1 trial)

levobupivacaine (chirocaine) (1 trial)

lidocaine (xylocaine) (1 trial)

melphalan (alkeran) (2 trials)

morphine (1 trial)

rifaximin (xifaxan) (1 trial)

rimabotulinumtoxinB (Myobloc) (1 trial)

rituximab (rituxan) (1 trial)

sevoflurane (ultane) (1 trial)

sodium bicarbonate (1 trial)

Drugs in Phase 2 Trials (14)

afatinib (gilotrif) (1 trial)

bevacizumab (avastin) (1 trial)

carboplatin (paraplatin) (2 trials)

cetuximab (erbitux) (2 trials)

eplerenone (inspra) (1 trial)

etoposide (vepesid) (2 trials)

fluorouracil (efudex) (1 trial)

irinotecan (Camptosar) (1 trial)

leucovorin (1 trial)

lolium perenne pollen (1 trial)

oxaliplatin (eloxatin) (1 trial)

umbilical cord mesenchymal stem cells (1 trial)

ustekinumab (stelara) (1 trial)

vincristine (oncovin) (1 trial)

Drugs in Phase 1 Trials (1)

Olesoxime (1 trial)

Drugs in Other Trials (12)

acetaminophen (tylenol) (1 trial)

apolipoprotein (1 trial)

cortivazol (1 trial)

gabapentin (neurontin) (1 trial)

heparin (liquaemin) (1 trial)

insulin human (humulin) (1 trial)

nitrous oxide (1 trial)

nusinersen (Spinraza) (1 trial)

platelet-rich plasma (1 trial)

prednisolone (hydeltra) (1 trial)

pregabalin (lyrica) (1 trial)

triamcinolone (kenalog) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 3)

Adenocarcinoma (Phase 3)

Ascites (Phase 3)

Colorectal Neoplasms (Phase 2)

Emergencies (Phase 3)

Hyperkinesis (Phase 3)

Ischemia (Phase 2)

Lymphoma (Phase 3)

Medulloblastoma (Phase 2)

Multiple Myeloma (Phase 3)

Multiple Sclerosis (Phase 1)

Multiple Sclerosis, Relapsing-Remitting (Phase 1)

Neoplasm Metastasis (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Pemphigoid, Bullous (Phase 2)

Peritonitis (Phase 3)

Pneumonia (Phase 3)

Pneumonia, Ventilator-Associated (Phase 3)

Prostatic Neoplasms (Phase 3)

Recurrence (Phase 3)

Renal Insufficiency (Phase 2)

Renal Insufficiency, Chronic (Phase 2)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Retinal Neoplasms (Phase 2)

Retinoblastoma (Phase 2)

Rhinitis, Allergic, Seasonal (Phase 2)

Sclerosis (Phase 1)

Syndrome (Phase 3)

Uterine Cervical Neoplasms (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 31
  • # of Trial APIs: 46